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Abstract
Introduction Medical and nursing protocols in perioperative care for pancreaticoduodenectomy are mainly mono-disciplinary,
limiting their integration and transparency in a continuous health care system. The aims of this study were to evaluate adherence
to a multidisciplinary clinical pathway for all pancreaticoduodenectomy patients during their entire hospital stay and to determine
if the use of this clinical pathway is associated with beneficial effects on clinical end points.
Materials and Methods A prospective cohort study was conducted in 95 pancreaticoduodenectomy patients treated according to
a clinical pathway, including a variance report, compared to a historical control group (n = 52) with a traditional treatment regime.
Results Process evaluation of the clinical pathway group revealed that protocol adherence throughout all units was above 80%.
Major complications according to Clavien-Dindo classification grade ≥3 decreased from 27 to 13%; p = 0.02. Hospital length of
stay was significantly shorter in the clinical pathway group, median 10 days [IQR 8–15], compared with the control group,
median 13 days [IQR 10–18]; p = 0.02.
Conclusion The use of a clinical pathway in pancreaticoduodenectomy patients was associated with high protocol adherence,
improved outcome and shorter hospital length of stay. Variance report analysis and protocol adherence with a Prepare-Act-
Reflect Cycle are essential in surveillance of outcome.
Keywords Pancreaticoduodenectomy . Clinical pathway .
Protocol adherence . Perioperative care
Introduction
Pancreaticoduodenectomy for pancreas tumours and
periampullary tumours is considered high-risk surgery and
is associated with high morbidity (30–70%) and a mortality
of 1–5% in specialized centres.1, 2 Centralization of pancreas
surgery and advances in surgical techniques resulted in more
patients being operated for advanced-staged tumours.3, 4
Patients with more comorbidity receiving pre-operative che-
motherapy and/or vascular reconstructions in advanced dis-
ease, need more complex perioperative care. Currently this is
facilitated by multiple guidelines and medical and nursing
protocols. This complexity demands an overall multidisciplin-
ary approach and clear communication.
Different departments are involved in the treatment during
the patients’ journey through the surgical ward, operation the-
atre, post-anaesthesia care unit (PACU) and intensive care unit
(ICU). However, large differences in the actual use of these
protocols are present between the different units and medical
and nursing staff members.5, 6 Moreover, while multidisci-
plinary teamwork for these patients is essential, the develop-
ment and implementation of a clinical pathway (CP) involve
many aspects of the total patient care and should therefore be
multidisciplinary by doctors and nurses as well.
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A CP may facilitate the care for this group of high-risk sur-
gery patients by unifying different protocols into one multidis-
ciplinary protocol for all units during the hospital stay of the
patients. This may result in an increased protocol adherence, less
morbidity and improved outcome. Key elements of a CP are
guidelines, evidence-based clinical protocols and best practice
rules, together with a coordinated sequence of activities of the
multidisciplinary team.7 Registration, monitoring and evaluation
of adherences, variances and outcomes are part of a CP and can
be part of a process-driven pathway.8 Amultidisciplinary CP has
therefore many evaluation moments and scheduled actions. To
keep the patient on the ‘pathway’, the CP mandates a registered
response of the nurse or doctor if results are outside the range of
the prescribed boundaries.
Many CPs have been developed for high volume with low-
risk and with average-risk health care procedures in order to
reduce complications.9–12 The post-operative phase of the pa-
tient spent in the ICU or PACU, however, is a seldom part of a
CP.13 A CP including the PACU/ICU stay mandates an hour-
to-hour care plan during the post-operative stay in the ICU/
PACU.14 Many standardized care plans related to a
pancreaticoduodenectomy have been published, focussing
on the use of an enhanced recovery program after surgery
(ERAS) with elements like early mobilization, early enteral
feeding, pain treatment and reduction of iv fluid administra-
tions to shorten the length of hospital stay.15–19 In these care
plans, a reduction of hospital length of stay (LOS), morbidity
or mortality was not always observed. Crucially, the ICU pe-
riod of these patients was not integrated in these protocols.
The aim of this study was first to determine the feasibility
to develop and implement a multidisciplinary CP including a
variance report for all pancreaticoduodenectomy patients dur-
ing their entire hospital stay and second to determine if the use
of this CP is associated with an improvement of patient’s
morbidity and outcome.
Methods
Setting and Patients
The Radboud University Medical Center in Nijmegen is a
1000-bed university hospital, including a 32-bed closed-format
ICU, a 5-bed PACU and a 30-bed gastrointestinal (GI) oncol-
ogy surgical ward. An anaesthesiologist with a resident are
supervising the PACU. The ICU is supervised by the
intensivists, with intensivists-in-training and residents. They
all work in close relation with the surgical team. On the surgical
ward, nurses, physician assistants and young residents are car-
ing for patients undergoing a pancreaticoduodenectomy, under
daily supervision of the senior GI-oncologymedical staff. Since
the centralization in 2012 of pancreas surgery in the
Netherlands, approximately 80 pancreas operations (60
malignant cases) are operated annually in the Radboudumc.
As a result, the logistics and perioperative care of our pancreatic
surgical program needed reflection and rescheduling.
Development of the CP
The development of the multidisciplinary CP for pancreatico-
duodenectomy was a multistep procedure with the use of les-
sons learned from the development and implementation of the
cardiac and oesophageal CPs, previously developed in
Radboudumc, and started in 2013.
The first step was redefining and searching for evidence un-
derneath the surgical, anaesthesiology and ICU protocols in the
perioperative period. This was a multidisciplinary procedure, un-
dertaken by the physician assistants, senior nurses, ‘key’ nurses
and medical staff.20–27 Instead of a traditional ‘day-to-day-care’
plan for the surgical ward, an ‘hour-to-hour’ care plan had to be
developed, including the PACU and ICU care. It was important
to identify potential barriers and facilitators in these settings, in
order to tailor the implementation strategy.28–31 An evidence-
based implementation strategy according to Grol was used.32
Second, a unique variance report (‘Radboud variance report’;
Appendix 1) had to be incorporated and developed together with
the CP.33 This Radboud model of variance report enables nurses,
physician assistants and young residents to execute predefined
actions in accordance with and within the preset boundaries of a
variance protocol, without having to wait for approval of the
responsible physician first (Dutch law and order for health care
professionals BWBR0006251 chapter IV, article 35).
Until 2012, a surgical pancreas matrix for (peri)operative
care was used at the surgical ward. The historical control
group was treated according to this matrix including the sur-
gical medical and nursing protocols without the variance re-
port. In the PACU and ICU, these patients were treated ac-
cording to different PACU and ICU protocols. This pancreas
matrix was used as backbone for further multidisciplinary de-
velopment of the CP. As part of the development and imple-
mentation strategy, a small group of key nurses responsible for
other CPs reflected on the concepts of the pancreas CP and
variance report as part of a Prepare-Act-Reflect (PAR) Cycle.
The pancreas CP had to be a continuum from admission to
discharge from the hospital. Essential elements included re-
strictive intra-operative fluid use, strict pain control, early mo-
bilization, early drain and tube removal and early enteral feed-
ing. Post-operatively, early warning scores (EWS) are mea-
sured at least once during every 8-h shift or more frequent,
whenever indicated by the nurses, with strict directives for
action by nurses according to the variance report.34
Patients with a malnutrition universal screening tool (MUST)
score above 2 need an active feeding intervention according to
the quality system of health care in the Netherlands. We decided
that patients with a MUST above 2 should start with total par-
enteral nutrition (TPN) within 24 h after surgery. Publications on
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calorie deficit and enteral feeding or TPN after surgery in ICU
patients often do not take into account malnutrition and MUST
score >2. Our protocol prescribes that if the gastric tube can be
removed, the patients need to start with oral/enteral feeding, and
TPN needs to stop as soon as the oral intake of the patients is
above 1000 kcal.22, 23, 35–37 TPN should be started on day 3 if
patients had aMUSTscore of 1 and enteral feeding had not been
started on day 3. All patients with a gastroparesis without signs
of sepsis or ileus on day 7 will be given a naso-jejunal tube by
the gastroenterologist through the gastrojejunostomy and start
enteral feeding.38 In contrast to ERAS-based protocols, devia-
tions from the CP had to lead into prompt actions according to
the variance report.
Implementation of the CP
After informative meetings for medical and nursing staffs,
including reflections on the positive aspects of previous CPs,
bedside training started on the surgical ward and PACU/ICU
in 2014. Implementation of the pancreas CP would introduce
an essential change in daily practice for most nurses, physician
assistants and medical staff. The first step in teaching was
getting acquainted to the CP vision that would result to one
continuous multidisciplinary protocol.32 In nursing and med-
ical staff meetings, updates of the project were discussed, and
feedback was welcomed by the CP developers. During this
teaching period, especially new PACU-specific aspects arose
for the pancreas CP, including new variance report criteria,
and as an interactive process of PAR cycles, these criteria were
incorporated in the pancreas CP during the development. In
this try-out period, feedback was asked and given every
4 weeks during the multidisciplinary team meetings of the
project. After 4 months of teaching and try-out period, it was
concluded that it was feasible and safe to use the pancreas CP
with the Radboud model variance report for patients during
their entire clinical stay, including the PACU/ICU. With the
completion of this implementation step, the pancreas CP was
considered being implemented and our study on the use of the
CP and variance report for all pancreaticoduodenectomy pa-
tients started on the first of September 2014, 18 months after
the start of the development of the CP, including many PAR
cycles. Patients treated for other pancreas procedures than
pancreaticoduodenectomy were considered candidates to
have the benefits of the pancreas CP during their stay in
PACU/ICU and ward, but were not included in this study.
Protocol adherence was measured per pathway action. We
considered protocol adherence if a deviation from the CP re-
sulted in the correct action, according to the CP, or if no action
was needed and no action was started. No protocol adherence
was defined as wrong actions or no actions if actions were
needed. Deviations from the CP had to be described in the
variance report or patient record.
Design
This is a pre-post design study. After the implementation of the
pancreas CP, patients treated according to the CP were com-
pared with a historical control group of patients treated with
standard perioperative care for pancreaticoduodenectomy ac-
cording to the original pancreas matrix and monodisciplinary
protocols and operated on between 2009 and 2012.
End Points
Primary endpoint was to determine the feasibility and safety,
including incidence of post-operative complications, according
to Clavien-Dindo classification, of the use the CP. Secondary
endpoints were in length of stay (LOS) in-hospital, post-
operative fluid balance, gastroparesis, protocol adherence to mo-
bilization, drain removal, radiologic and surgical re-interven-
tions, ICU readmission, hospital readmission and mortality rate.
Statistics
Continuous variables were described as median and interquartile
range [IQR] and tested with the Mann-Whitney U test.
Differences in dichotomous variables were analyzed using the
chi-squared test. Due to the exploratory nature of this study, and
to increase the sensitivity to detect differences between groups,
no correction for multiple testing was performed. With our con-
venience sample size of 95 patients in the CP group and 52
patients in the control group, our study had 80% power to dem-
onstrate a 7% absolute reduction of post-operative complica-
tions. All statistical analyseswere performed using SPSS version
20.01 for Windows (IBM, SPSS statistics, Chicago, IL, USA).
Results
Development Results of the CP
Nurses, physiotherapists, dieticians and medical staff special-
ized in pancreas surgery contributed to the development of the
pancreas CP and the variance report. This resulted in a set-up
of clear and safe boundaries in taking clinical treatment deci-
sions and an upscaling system to consultation with a key nurse
or senior staff members, if actions according to the variance
report did not seem right.
First, the pancreas CP for medical and nursing decisions
was written according to existing evidence-based protocols,
best practices and guidelines. Finally, a multidisciplinary var-
iance report was incorporated (Appendix Table 4: summary of
the differences between CP and control surgery and
Appendices 2 and 3: variance report).
For the analysis of the developmental process, we evaluated
barriers and facilitators for protocol adherence. For this,
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interviews and questionnaires were used, focussing on possible
barriers and facilitators for protocol adherence to the new CP. An
important facilitator was the motivation of nursing and medical
staff to ask for guidance and training in the use of this protocol.
The most important barrier was that using the protocols was
experienced as a time consuming processes of getting acquainted
with the system, resulting in feelings of loss of autonomy for
doctors and nurses. Key nurses together with medical leadership
were essential for awareness, feedback and motivation during
development, implementation and the use of the CP.
Implementation Results of the CP
First, the medical aspects of the CP were implemented on the
ward followed by the nursing aspects. Because of the lack of
experience with CPs, the care providers working on the PACU
received more time for training and bedside teaching and started
later with implementation. Key nurses at the surgical ward gave
guidance and were partner for the key nurses of the PACU.
Evaluation after the implementation process was per-
formed every 2 months during the first 6 months and after this
period whenever needed. These evaluations resulted mostly in
questions or new ideas for a change in the CP from the units or
when less compliance was observed. The variance report was
an important tool for evaluating compliance. When compli-
ance of one of the CP domains was below 80%, feedback was
given by the key nurse or surgeon through focussed teaching
sessions for nurses and residents.
After a period of 18months, the pancreas CPwas implement-
ed and evaluation of protocol adherence was 80% for
PACU/ICU periods and 60% for the surgical ward. The latter
was mainly influenced by a low compliance to drain removal
(<50%). According to the pancreas CP, drain removal was
allowed if amylase level in the drain was below 500 U/l and
volume below 200 ml/day. Deviations turned out to be primarily
a system problem of postponing drain removal during weekends.
After recognition of this system problem, an active policy started
and protocol adherence on this item improved to above 80%.
Following the implementation, in September 2014, the out-
come study of the pancreas CP was started (Fig. 1 implemen-
tation flowchart).
Clinical Outcomes
Between September 2014 and September 2016, in total, 95 elec-
tive consecutive pancreaticoduodenectomy patients were treated
within the pancreas CP. Semi-acute pancreaticoduodenectomies
(for bleeding tumours) and other types of resections (e.g. total
pancreatic resections or pancreaticoduodenectomies with resec-
tion of a secondary colorectal tumour) were no part of the study.
A cohort of 52 consecutive elective pancreaticoduodenectomy
patients treated before the CP implementation period between
2009 and 2012 was identified as historical control group. Their
perioperative treatment had been according to the underlying
matrix protocol that was used as base for the development of
the CP. Three surgeons in the pre-CP period operated on the
pancreaticoduodenectomy patients. Results between these sur-
geons did not differ, and perioperative care was regulated by
protocols. These surgeons were also responsible for pancreas
surgery in the CP period.
Baseline characteristics between the two groups were not
significantly different, apart from a higher number of CP pa-
tients receiving portal vein resection or celiac trunk/superior
mesenteric artery (SMA) vessel exploration (Table 1).
Intra-operative Data
The median intra-operative amount of fluids administered was
3900 ml [IQR 3000–4600] in the CP patients versus 5200 ml
[IQR 4000–6000] in the control group (p < 0.001). Post-
operative fluid balance and fluid balance on day 1 post-
operative were also significantly lower in the CP group versus
the control group (p< 0.001; Table 2). Althoughmore portal vein
resections and celiac trunk and explorations along the SMAwere
performed, blood loss was less in the CP patients: 755 ml [IQR
500–1100] versus 1303ml [IQR 656–2402] (p < 0.001, Table 2).
Post-operative Data
Adherence of pain and hemodynamic interventions according to
the variance report was 100% at the PACU/ICU, and a step-up
approach regarding pain control was adequately used according
to CP protocol. Hemodynamic interventions in accordance with
the variance report were not needed and not started in 17%of the
CP patients, and 57% of the CP patients needed an extra hemo-
dynamic intervention which was subsequently started according
to the CP protocol. In total, 26% of the patients were treated with
vasopressors on arrival in the PACU/ICU, which could be re-
duced during their stay. Significantly more CP patients were
swing mobilized within 24 h compared with the control group,
respectively, 83 versus 19%, p = 0.001. Especially poor pain
control and patients’ feelings of weakness, early after the oper-
ation, were recorded as reasons not to start swing ormobilization
at the surgical ward. Trigger for complications was the EWS; in
32% of the patients in the CP group, the EWS was above 3.
Interventions on a high EWSwere adequate and according to the
variance report >95% of the patients.
Considering clinical outcome, major complications accord-
ing to the Clavien-Dindo classification grade 3 or more oc-
curred less frequently (13 vs 27%, p = 0.02) in the CP group,
compared to the control group.39 One patient had a Clavien-
Dindo 4b complication as a result of pancreatic leakage com-
plicated by sepsis with EWS >6 on day 7 and hemorrhagic
bleeding on day 14 in the CP group. This complication was
successfully treated by radiologic coiling of the gastroduode-
nal artery and splenic artery.
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Less patients suffered from gastroparesis grades B and
C in the CP group compared to the control group, 9 ver-
sus 62%, p < 0.001, as were radiologic interventions: 11
versus 27%, p = 0.04. In the control group, the gastric
tube was not removed when production was reduced but
was left in place and blocked and could be removed if
after measurement of retention after 8 and 16 h, it was
less than 100 ml per 8 h. Pancreatic leakage and chylus
leakage, readmission to ICU and readmission to hospital
did not significantly differ between the CP group and
control group. Median times to drain removal were also
not influenced. The mortality rate was low and not differ-
ent between groups (Table 3).
Discussion
This study illustrates that development of a CP for
pancreaticoduodenectomy is an iterative multidisciplinary pro-
cess, starting with a dynamic protocol with improvements
through PAR cycle evaluation and change moments.
Implementation of the pancreas CP in all units involved in the
entire (peri-) operative process (OR, PACU/ICU/surgical ward)
took 18 months. Process evaluation of the prospective CP group
revealed that protocol adherence was successfully achieved in
>80% for most of the criteria throughout the clinical stay.
Comparison of both cohort groups on main clinical outcomes
showed that major complications according to the Clavien-
Table 1 Baseline characteristics
of pancreas CP and control
groups of
pancreaticoduodenectomy
Clinical pathway, N = 95 Control, N = 52 P
Age, median (IQR) 66 (57–72) 66 (58–72) 0.98
Male, n (%) 56 (58.9) 35 (67.3) 0.26
Stent/(PTC) percutaneous drainage, n (%) 59 (61.5) 28 (53.8) 0.34
Pulmonary comorbidity, n (%) 13 (13.7) 4 (7.7) 0.52
Cardial comorbidity, n (%) 13 (13.7) 10 (19.2) 0.62
Vascular comorbidity, n (%) 29 (30.5) 16 (30.8) 0.80
Diabetes, n (%) 21 (22.1) 16 (31.4) 0.4
Preoperative chemotherapy, n (%) 4 (4.2) 0
Portal vein resection, n (%) 20 (21.1) 1 (1.9) <0.001
Celiac trunk/SMA exploration, n (%) 6 (6.3) 0
IQR first and third interquartile range, PTC percutaneous transhepatic cholangiography, SMA superior mesenteric
artery
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Fig. 1 Implementation of pancreas CP and study flowchart
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Dindo classification grade 3 or more and hospital LOS in the CP
group were significantly lower compared to the control group. In
addition, implementation of the CP was associated with a reduc-
tion of gastroparesis, an improved post-operative fluid balance,
and patients in the CP group were more likely to receive early
mobilization and adequate actions on EWS above 3. These data
illustrate that implementation of a CP in this specific group of
patients is feasible, safe and likely to be beneficial for the patient.
Analyzing reasons not to follow the variance report was
part of this study. Human factors were often reasons for devi-
ation from the report, for example, insecurity of young pro-
fessionals on decisions leading to postponing gastric tube re-
moval. The prevention of gastroparesis is part of a very active
PAR cycle in the CP. Nurses, young doctors and patients want
to prevent discomfort for the awake patient while reposi-
tioning the tube, even if early removal is according to proto-
col. The action was a team reflection on the discomfort of a
needless gastric tube for too long and, as a result, delay in
starting early oral nutrition and well-being.
Postponing early mobilization because of patients’ pain or
weakness did occur. In all situations, the iterative process of
repeated and specific education was important to explain the
reasons behind the CP and guidance.
Considering the diverse landscape of CPs and surgical care
plans, it is difficult to compare the different studies. In studies,
related to implementation of CPs, not all hospital wards in-
volved in the clinical process (like PACU/ICU) were included,
which negatively influences the continuous care process for
the patient. Also different treatment regimes make reliable
comparison and evaluation of different CPs difficult.
Regarding the available studies, we found only studies not
covering the whole clinical stay, excluding parts of the post-
operative period. In these studies usually some specific aspects
like ERAS, drain and gastric tube removal were addressed.18
A standardized care plan for pancreaticoduodenectomy pa-
tients was retrospectively studied in another study focussing
on predictors of LOS in-hospital.15 Specific ERAS pathways,
without PACU/ICU periods involved, focussed on in-hospital
LOS, outcome mortality and morbidity. While these were un-
changed, measurement of protocol adherence was not part of
the study.16 Braga et al. evaluated the compliance to the en-
hanced recovery protocol and concluded that patients with
low compliance had a higher incidence of complications.40
Our results are in pursuance of previous studies that
showed that a CP or standardized care plan for pancreatico-
duodenectomy patients resulted in an earlier start of solid en-
teral feeding and a shorter hospital LOS and less readmissions.
Importantly, protocol adherence to predefined targets has not
been part of these studies as was analysis of the reasons not
following the protocol and its association to outcome.
Comparing our study to these studies, a similar effect on
reduction of complications, hospital LOS, readmissions,
gastroparesis, time to enteral feeding and time to mobilization
was found. Our present study also illustrates that it is feasible
to implement a CP that covers the entire clinical admission,
applying different targets of the various involved units (e.g.
focus on hemodynamic and respiratory vital parameters at the
PACU/ICU, versus focus on EWS and ERAS criteria at the
Table 3 Post-operative data of pancreas CP and control groups of
pancreaticoduodenectomy
Clinical
pathway,
N = 95
Control,
N = 52
P
Post-operative PACU, n (%) 81 (85) 29 (55) 0.002
Mobilization swing,
according to protocol
(within 24 h) n (%)
78 (83) 10 (19) 0.02
Mobilization out of bed in
days, median (IQR)
2 (1–2) 2 (2–3.3) 0.001
Gastroparesis (ISGPS): n (%)
• Type A 20 (21) 15 (29) <0.001
• Type B 7 (7) 18 (35)
• Type C 2 (2) 14 (27)
Pancreas leakage, n (%) 12 (13) 5 (10) 0.82
Drain in situ (days), median (IQR) 6 (4–10) 7 (5–12) ns
Clavien-Dindo classification n (%)
3a 9 (10) 9 (19) 0.02
3b 1 (1) 4 (8)
4b 1 (1) 0
5 1(1) 0
Radiologic reintervention, n (%) 10 (11) 14 (27) 0.04
Relaparotomy, n (%) 3 (3) 4 (8) 0.01
Readmission ICU, n (%) 7 (7) 7 (14) ns
Readmission hospital, n (%) 12 (13) 9 (18) ns
LOS in-hospital (days),
median (IQR)
10 (8–15) 13 (10–18) 0.02
30-day mortality, n (%) 1 (1) 0 ns
90-day mortality, n (%) 2 (2) 1 (2)
Table 2 Intra-operative results of pancreas CP and control groups of pancreaticoduodenectomy
Fluid and vasopressor management Clinical pathway, N = 95 Control, N = 52 P
Intra-operative fluids (ml), median (IQR) 3900 (3000–4600) 5200 (4000–6000) <0.001
Fluid balance, at the end of the procedure, median (IQR) 405 (−107 to 833) 1926 (1253–2818) <0.001
Intra-operative blood loss, median (IQR) 755 (500–1100) 1303 (656–2402) <0.001
Intra-operative vasopressor use, n (%) 94 (99) 48 (92) 0.22
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surgical ward). Nurses were also able to start adequate therapy
in accordance with the variance rapport when EWS deviated
from the target. Moreover, new to the other studies is that this
study, via the variance report method, exposed the barriers and
facilitators of CP adherence. In addition, these two monthly
formal meetings to evaluate variance report deviations and
their barriers and facilitators enabled us to discriminate the
difference of loss of compliance to a protocol due to compli-
cated discourse of operations, versus loss of professional ad-
herence to the CP protocol.
The current study has several limitations. Most importantly,
this is a single-centre pre-post-intervention study. The intensity
and duration to develop the CP, as well as the implementation
process, limit the feasibility of using other study designs. In
addition, the historical group was not formally matched, which,
together with the fact that no randomization was carried out,
induces a higher risk of confounding factors. No relevant differ-
ences in patient characteristics between the different study pe-
riods were observed. However, the case load per surgeon in-
creased, which could be considered as a possible confounding
factor. We considered the development of a CP as the most
appropriate intervention to re-schedule the process. Prospective
complication registration was part of the daily supervised peri-
operative care as well as the discharge procedure in both groups.
Moreover the prospective database on outcome and complica-
tions of the control group (2009–2012) served as a document to
identify barriers and facilitators for building the CP. Furthermore,
no relevant changes in other procedures, staffing levels, technical
infrastructure or other major changes that could influence patient
management occurred, and during the whole study period, there
were no changes in interventions that are known to influence
morbidity or mortality in the ICU such as strict glucose regula-
tion, early goal-directed therapy, use of corticosteroids, prone
positioning and low tidal volume ventilation. Second, no a priori
power calculation was carried out, implying that the risk for a
type 1 or 2 error has not been overcome. Using our convenience
sample, we did calculate that our study has 80% power to dem-
onstrate a 7% change in complication rate, while we observed
that the complication rate halved. Nevertheless, the sample size
of the study and the discussed design issues should make us
aware of the possible overestimation of the outcome differences.
In contrast, this does not necessarily apply for the process anal-
ysis part. As no comparison of the CP group was made to the
control group, the conclusions of the process analysis merely
indicate that CP development, implementation and high level
of adherence to such a CP, throughout all units involved in the
perioperative process, are feasible within a relative short period
and up to a high standard.
Lessons Learned
This study shows us, in line with the implementation of our
cardiac surgery CP and oesophageal surgery CP,41 that it is
feasible to develop and implement a CP for pancreatico-
duodenectomy procedures for all involved units like the
PACU/ICU and surgical ward through the entire clinical
perioperative period. In all units, the CP targets need to be
aligned and the use of a variance report discriminates
complication-related to failure of professional adherence.
Implementation is an iterative process that takes time to
become comfortable in use for all involved units. Key nurses
together with medical leadership were essential for aware-
ness, feedback and motivation during development, imple-
mentation and the use of the CP.
Future Perspectives
In order to overcome the methodological drawbacks of this
study and to validate the CP methods, a multicenter stepped-
wedged cluster randomized controlled trial would be ideal.
However, due to the complexity of the implementation and
intervention with barrier and facilitator analysis in different
hospitals and units, interpretation of the results will be diffi-
cult. Exploring the validity of similar CPs is in line with the
need for quality assurance of standardized treatment regimes
with high protocol adherences.
For the near future, continuous monitoring, wearables and
electronic medical data recording with pop-up facilities warn-
ing medical and nursing staff for deviations from the CP will
likely be of help in building more complex pathways.
Possibly, patients with high comorbidity will be able to follow
their personalized clinical pathway (pCP) with the help of
dedicated staff.
Conclusion
The use of the CP was associated with a reduction of periop-
erative morbidity. Essential new tools include a variance re-
port analysis, scheduled barrier and facilitator analyses and the
iterative PAR cycle protocol development, performed by a
multidisciplinary team. Development, implementation and
use of a CP throughout the hospital stay for patients undergo-
ing pancreaticoduodenectomy are a multistep procedure in
which we showed that this is feasible and safe.
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Table 4 Similarities and differences between clinical pathway and control period
Clinical pathway Control
Outpatient
clinic
Tumour board treatment advice (PACON) Tumour board treatment advice (PACON)
Oral and written patient information Oral patient information
Dietician contact: MUST screening tool, nutrition advice and if needed
supplemental feeding oral or enteral
Dietician contact if needed supplemental feeding oral or enteral
Frailty screening tool
Medication verification
Training advice: home trainer use, 1-h walking per day
Surgical
ward
Use of ERAS protocol Use of ERAS protocol
Preoperative lanreotide® Preoperative lanreotide®
Thrombosis prophylaxis nadroparine® 5700 E Thrombosis prophylaxis nadroparine® 2850 E
6:00 day of operation: last preop or clear liquid intake, anti-thrombosis
compression stockings.
Pain management and control according to protocol together with pain
service team
Pain management together with pain service team
Early warning score once per 8 h and whenever indicated together with
actions by nurses
Early warning score once per 8 h and whenever indicated action
by resident
Patient communication between doctors, nurses and handover situations
according to Reason, Story, Vital Signs and Plan (RSVP)
Patient communication between doctors, nurses and handover
situations not specified
Mobilization after surgery: swing and out of bed within 24 h Mobilization after surgery: swing and out of bed within 24 h
Gastric tube: if production <200 ml in 12 h, remove tube Gastric tube: if production is reduced, start clamp tube and
remove if retention is <100 ml in 8 h (after two consecutive
periods of 8 h)
Drain removal if production <200 ml and amylase <500 U/l per day Drain removal if amylase <500 U/l per day and operating
surgeon agrees
Nutrition: MUST >2, start TPN on day 1 post-operative Nutrition: enteral feeding will start on day 1 if the patient has a
jejunostomy. Oral fluids according to ERAS
MUST = 1: if gastric tube has not been removed on day 3, start TPN If no enteral intake is possible on day 6, TPN has to start on day 7
All patients: if the gastric tube cannot be removed because of
gastroparesis on day 7 without signs of sepsis or ileus: placement of a
jejunal tube through the gastrojejunostomy by the gastroenterologist
and start enteral feeding
Glucose control Glucose control
Discharge criteria Discharge criteria not specified
Use of the variance report if actions are not according to protocol.
Operating
room
Use of ERAS protocol Use of ERAS protocol
Pain control by epidural catheter Pain control by epidural catheter
Central venous line in the vena jugularis, if indicated PiCCO
Antibiotic prophylaxis 15–60-min pre-incision. Cefazoline® and
metronidazole®. If a stent or percutaneous transhepatic drain has been
placed in the ductus choledochus, use piperacillin/tazobactam® as
prophylaxis.
Antibiotic prophylaxis 15–60-min pre-incision. Cefazoline® and
metronidazole®. Otherwise if indicated by the surgeon
Target post-operative fluid balance between 0 and 500 ml Post-operative fluid balance not specified but according to ERAS
Handover to PACU team members by surgeon and anaesthesiologist
according to RSVP
Handover to PACU team members by anaesthesiologist
PACU/ICU Entrance in PACU: every 15 min: RR and heart rate control until stable,
than every 30 min RR and pulse
Entrance in PACU: every 15 min: RR and pulse control until
stable than every 30 min RR and pulse
Continuation of antibiotics will be part of the sign-out procedure after
surgery
Continuation of antibiotics at the decision of the surgeon
Normothermia (>36.0 °C), Bair Hugger or heating system if necessary Normothermia (>36.0 °C), Bair Hugger or heating system if
necessary
Every hour (1st until 24th hour):
Respiratory status after extubation: saturation, respiratory frequency,
coughing and deep breathing exercises
Every hour (1st until 24th hour):
Respiratory status after extubation: saturation, respiratory
frequency, coughing and deep breathing exercises
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Table 4 (continued)
Clinical pathway Control
Hemodynamics: heart rhythm, heart frequency, RR, ScvO2 (if
indicated).
Excretions: urine, drain, gastric tube
Hemodynamics: heart rhythm, heart frequency, RR, ScvO2 (if
indicated).
Excretions: urine, drain, gastric tube
Temperature Temperature
Pain and sedation: NRS pain score Pain and sedation: NRS pain score
RASS and CAM ICU RASS
Mean arterial pressure (MAP) between 70 and 100 mmHg and heart
frequency between 60 and 90 per minute. Different targets than the
CP prescribe possible after approval of the supervising
anaesthesiologist .
Mean arterial pressure (MAP) targets need approval of the
supervising anaesthesiologist.
MAP should be above 70 mmHg: if below, start norepinephrine.
iv fluids: ERAS protocol
Balance between 0 and +500 ml/24 h
Urine production has to be above 0.5 ml/kg/h. Protocol ‘oliguria PACU’ Urine production has to be above 0.5 ml/kg/h. Protocol ‘oliguria
PACU’
First choice of inotropics: dobutamine® First choice of inotropics: supervising anaesthesiologist
Stress ulcer prophylaxis pantoprazole® 1 dd 40 mg iv/po Stress ulcer prophylaxis pantoprazole® 1 dd 40 mg iv/po
Nausea and vomiting:
3/day 4 mg ondansetron® iv (maximum until 36 h after surgery)
3/day metoclopromide® 3/day 10 mg iv (3/day 5 mg iv when kidney
function reduced) (cave QT time)
Nausea and vomiting:
If indicated: 3/day 4 mg ondansetron® iv
If indicated: 3/day metoclopromide® 3 day 10 mg iv (3/day
5 mg iv when kidney function reduced) (cave QT time)
Anti-thrombosis prophylaxis nadroparine® 5700IE Anti-thrombosis prophylaxis nadroparine® 2850 IE
Mobilization according to protocol: starts within 24 h
Gastric tube: see CP surgical ward Gastric tube
Drain: 2 abdominal drains
Drain production control every hour: aspect and volume, 100–200 ml/h.
If production >200 ml/h or >400 ml/4 h, contact surgeon
Drain: 2 abdominal drains
Drain production control every hour: aspect and volume,
100–200 ml/h. If production >200 ml/h or >400 ml/4 h,
contact surgeon
Electrolyte control and interventions Electrolyte control and interventions
Glucose regulation: normoglycaemia (glucose 5.0–10.0 mmol/l) Glucose regulation: normoglycaemia (glucose 5.0–10.0 mmol/l)
Discharge criteria: handover procedure according to RSVP, vital signs
accepted by the surgical ward.
Discharge criteria according to PACU
Use of the variance report if actions are not according to protocol.
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